Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A pharmacoeconomic model comparing two long-acting treatments for overactive bladder.

Les Noe1, Russell Becker, Todd Williamson

  • 1Ovation Research Group, 600 Central Avenue Suite 265, Highland Park, IL 60035, USA.

Journal of Managed Care Pharmacy : JMCP
|November 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reducing Opioid Utilization After Ureteroscopy Without Compromising Patient Outcomes in a Statewide Quality Improvement Collaborative.

Urology·2026
Same author

Change in urine albumin-to-creatinine ratio and clinical outcomes in patients with chronic kidney disease and type 2 diabetes.

BMJ open diabetes research & care·2025
Same author

Changes in urine albumin-to-creatinine ratio and health care resource utilization and costs in patients with type 2 diabetes and chronic kidney disease.

Journal of managed care & specialty pharmacy·2025
Same author

Guideline-directed medical therapies (GDMTs) for chronic kidney disease with type 2 diabetes (CKD + T2D): Translation of lessons learned from the management of heart failure.

Journal of diabetes and its complications·2025
Same author

Area deprivation index predicts annual chronic kidney disease screening and chronic kidney disease development among patients with newly diagnosed hypertension and type 2 diabetes in a large midwestern health system: a retrospective cohort study.

BMJ public health·2025
Same author

Long-Term Outcomes of Heart Failure With Preserved or Mid-Range Ejection Fraction in the United States.

JACC. Advances·2024
Same journal

Should eligibility for medication therapy management be based on drug adherence?

Journal of managed care pharmacy : JMCP·2014
Same journal

Medication adherence in a sample of elderly suffering from hypertension: evaluating the influence of illness perceptions, treatment beliefs, and illness burden.

Journal of managed care pharmacy : JMCP·2014
Same journal

Pharmacists' role in the care of patients with heart failure: review and future evolution.

Journal of managed care pharmacy : JMCP·2014
Same journal

PCMHs, ACOs, and medication management: lessons learned from early research partnerships.

Journal of managed care pharmacy : JMCP·2014
Same journal

Adherence to national recommendations for safe methotrexate dispensing in community pharmacies.

Journal of managed care pharmacy : JMCP·2014
Same journal

Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel.

Journal of managed care pharmacy : JMCP·2014
See all related articles

Extended-release tolterodine is slightly less costly for overactive bladder (OAB) than controlled-release oxybutynin. This cost-minimization analysis suggests tolterodine as a potentially more economical first-line OAB treatment.

Area of Science:

  • Pharmacoeconomics
  • Urology
  • Health Economics

Background:

  • Overactive bladder (OAB) is a common condition impacting quality of life.
  • Pharmacologic therapy is a cornerstone of OAB management.
  • Comparing the cost-effectiveness of different OAB medications is crucial for healthcare providers and payers.

Purpose of the Study:

  • To estimate and compare the first-line treatment costs of extended-release tolterodine and controlled-release oxybutynin for OAB.
  • To analyze resource consumption and cost impact from a payer's perspective.

Main Methods:

  • A decision-analysis model was developed using published literature and expert opinion.
  • The model focused on cost-minimization, assuming equal efficacy between treatments.
  • Costs were estimated from a payer perspective in 2000 U.S. dollars.

Related Experiment Videos

Main Results:

  • Estimated 3-month treatment costs were $1,207 for extended-release tolterodine versus $1,283 for controlled-release oxybutynin, a 6.3% difference.
  • Direct drug costs represented 19% of total costs for tolterodine and 15% for oxybutynin.
  • Sensitivity analysis confirmed the stability of these findings.

Conclusions:

  • Extended-release tolterodine appears to be slightly less costly than controlled-release oxybutynin for initial pharmacologic therapy in OAB patients.
  • Further direct comparative studies are needed to definitively establish the most cost-effective treatment approach for OAB.